Journals / Hacettepe Journal of Biology and Chemistry / 2021 / Cilt: 49 - Sayı: 1

Development and Validation of a Quantification Method for L-Dopa inPlants and Pharmaceutical Materials

Bitkilerde ve Farmasötik Materyallerde L-Dopa için Analiz Metodunun Geliştirilmesi ve Validasyonu

Pages
1–10
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Developed method has been successfully used for the determination of L-Dopa in pharmaceutical formulations and plant materials.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:L-Dopa is an antiparkinsonian drug and is used per oral application.
📊
Key Findings & Data:The analysis has been carried out using Ace C18 (5 μm, 4.6 x 250 mm,) column, and the separation was carried out using a mobile phase consisting of 50 mM potassium dihydrogen phosphate (pH 2.3) at a flow rate of 1.2 mL min-1 with UV detection at 280 nm.
💡
Conclusion & Impact:Developed method has been successfully used for the determination of L-Dopa in pharmaceutical formulations and plant materials.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

L-Dopa is an antiparkinsonian drug and is used per oral application. A reliable liquid chromatographic method for determination of L-Dopa in leaves, flowers and seeds of Vicia faba L. grown in Turkish habitats and pharmaceutical dosage forms has been developed. The analysis has been carried out using Ace C18 (5 μm, 4.6 x 250 mm,) column, and the separation was carried out using a mobile phase consisting of 50 mM potassium dihydrogen phosphate (pH 2.3) at a flow rate of 1.2 mL min-1 with UV detection at 280 nm. The method has been validated according to the acceptance criteria of the ICH guidelines. The method demonstrated good linearity (R2 > 0.999) over the assayed concentration range, good intra-day and inter-day precision. The detection limit (LOD) and the quantification limit (LOQ) values were determined as 1.70 and 5.13 μg mL-1 for L-Dopa. Developed method has been successfully used for the determination of L-Dopa in pharmaceutical formulations and plant materials.

Özet

L-Dopa antiparkinson ilaçtır ve oral uygulama için kullanılır. Türk habitatlarında yetiştirilen Vicia faba L.’nin yapraklarında,çiçeklerinde ve tohumlarında ve farmasötik dozaj formlarında L-Dopa’ nın belirlenmesi için güvenilir bir sıvı kromatografikmetod geliştirilmiştir. Analizler Ace C18 (5 μm, 4.6 x 250 mm,) kolon kullanılarak yapıldı ve ayırma, 1.2 mL min-1 akış hızında 50mM potassium dihydrogen phosphate (pH 2.3) içeren bir mobil faz kullanılarak 280 nm de UV deedektör ile gerçekleştirildi.Metod, ICH yönergelerinin kabul kriterlerine göre valide edilmiştir. Metod, analiz edilen konsantrasyon aralığında iyidoğrusallık (R2> 0.999), gün içi ve günler arası kesinlik gösterdi. L-Dopa için teşhis limiti (LOD) ve tayin limiti (LOQ) değerleri1.70 ve 5.13 μg mL-1 olarak belirlenmiştir. Geliştirilen metod, ilaç formülasyonlarında ve bitki materyallerinde L-Dopa’ nınbelirlenmesi için başarıyla kullanılmıştır.

🔖

Cite This Article

BULDUK, İ., TOPAL, N. (2022). Development and Validation of a Quantification Method for L-Dopa inPlants and Pharmaceutical Materials. Hacettepe Journal of Biology and Chemistry, Cilt: 49 - Sayı: 1, 1–10. https://ajindex.com/articles/528953

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. S. Fahn, D. Oakes, I. Shoulson, K. Kieburtz, A. Rudolph, A Lang, C.W. Olanow, C. Tanner, K. Marek, L-DOPA and the progression of Parkinson’s disease, New Engl. J. Med., 351(2004) 2498–2508
  2. C.E. Clarke, M. Guttman. Dopamine Agonist Monotherapy in Parkinson’s Disease. Lancet, 360 (2002) 1767–1769
  3. M. Rezak, Current pharmacotherapeutic treatment options in Parkinson’s disease, Dis. a Month, 53 (2007) 214–222. 4.
  4. D. Goncalves, G. Alves, P. Soares-da-Silva, A. Falcão, Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review, Anal. Chim. Acta, 710 (2012) 17–32. 6.
  5. F.J. David, M.R. Rafferty, J.A. Robichaud, J. Prodoehl, W.M. Kohrt, D.E. Vaillan-court, D.M. Corcos, Progressive resistance exercise and Parkinson’s disease: a review of potential mechanisms, Parkinson’s Dis, (2011) 124527
  6. J.M. Cedarbaum, R. Williamson, H. Kutt, Simultaneous determination of L-DOPA, its metabolites and carbidopa in clinical samples, J. Chromatogr. B: Biomed. Sci. Appl., 415 (1987) 393–399
  7. Y. Michotte, M. Moors, D. Deleu, P. Herregodts, G. Ebinger, Simultaneous Determination of Levodopa, Carbidopa, 3-O-methyldopa and dopamine in plasma using high- performance liquid chromatography with electrochemical detection, J. Pharm. Biomed. Anal., 5 (1987) 659–664
  8. D.C. Titus, T.F. August, K.C. Yeh, R. Eisenhandler, W.F. Bayne, D.G. Musson, Simultaneous high-performance liquid chromatographic analysis of carbidopa, L-DOPA and 3-O-methyldopa in plasma and carbidopa, L-DOPA and dopamine in urine using electrochemical detection, J. Chromatogr. B: Biomed. Sci. Appl., 534 (1990) 87–100
  9. K.A. Sagar, M.R. Smyth, Simultaneous determination of L-DOPA, carbidopa and their metabolites in human plasma and urine samples using LC-EC, J. Pharm. Biomed. Anal., 22 (2000) 613–624
  10. V. Rizzo, M. Memmi, R. Moratti, G. Melzi d’Eril, E. Perucca, Concentrations of L-Dopa in plasma and plasma ultrafiltrates. J. Pharm. Biomed. Anal., 14 (1996) 1043–1046
  11. T. Wikber, Simultaneous determination of L-DOPA, its main metabolites and carbidopa in plasma by liquid chromatography, J. Pharm. Biomed. Anal., 9 (1991) 167–176
  12. M. Karimi, J.L. Carl, S. Loftin. J.S. Perlmutter, Modified high- performance liquid chromatography with electrochemical detection method for plasma measurement of L-DOPA, 3-O-methyldopa, dopamine, carbidopa and